327 results about "Anti coagulation" patented technology

A system for minimizing and/or eliminating coagulative or mineral deposits on respective blood-contacting surfaces of implanted medical devices includes an implantable system having a current generating device that is electrically coupled to at least first and second electrodes for developing a current therebetween. The at least first and second electrodes are disposed across a patient's thoracic cavity in a manner so that a particular implanted medical device having at least a portion thereof that is fabricated from an electrically conductive material is disposed in a path substantially between such electrodes, thereby focusing the generated electrical current at the electrically conductive portion of the implanted medical device for therapeutic treatment thereat.

An electronic anti-coagulation stent structure is disclosed. The stent structure comprises a pair of coaxial metal stents having a layer of dielectric material between the stents. A battery is operatively connected preferably near or adjacent to the upstream end upon deployment of the stent. The positive battery terminal establishes an electrical connection to the outer metal stent and the negative terminal establishes an electrical connection to the inner metal stent and this exhibits a capacitor-like properties. The inner metal stent, being negatively charged, promotes a platelet repellent, anti-thrombotic effect.

Aiming at the conditions that heparin has severe bleeding side effects in clinical practice and clinical application thereof is restricted, the invention discloses a technique for producing ultra-low molecular heparin sodium (calcium). The technique comprises the following steps of: taking heparin sodium solution, adding sodium nitrite solution for cracking; adjusting the lysis buffer by using alkaline; absorbing impurities by using an anion-exchange column; washing for obtaining ultra-low molecular heparin calcium; carrying out filtration by using an ultrafiltration membrane and obtaining a precipitate by using alcohol; and after desalting, dehydration, re-precipitation, cooling and drying, obtaining a finished product of ultra-low molecular heparin calcium. The product has better and safer antithrombotic effect under low level of anticoagulation, and can be widely used for preventing and treating diseases such as deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, and the like.

The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.

Novel polypeptides or derivatives comprising the factor VIIIa binding site on factor IXa are disclosed. The novel polypeptides or derivatives have anti-coagulation activity. Nucleic acids encoding those polypeptides are also disclosed. Methods for identifying an agent having anti-coagulation activity are also disclosed. These methods comprise determining whether the agent displaces the polypeptide or derivative from its factor VIIa binding site. The agent identified in these methods is also useful in methods for treating a patient to prevent thrombosis. The treatment methods comprise administration of the agent to the patient. Additional methods are also disclosed for treating a patient to prevent thrombosis, comprising treating the patient with a polypeptide or derivative comprising the factor VIIIa binding site on factor IXa. Methods of preventing coagulation in a blood sample are also disclosed, comprising adding the polypeptides or derivatives described above to the blood sample. Methods of detecting factor VIIIa in a sample are also disclosed. Those methods comprise contacting the sample with the above-described polypeptide or derivative, wherein the polypeptide or derivative also comprises a covalently attached detectable moiety, then determining whether the polypeptide or derivative is binding factor VIIIa from the sample.

The invention discloses liquid-base cell preservation liquid as well as a preparation method and application thereof, relating to the technical field of biology. The liquid-base cell preservation liquid contains the following components in parts by weight: 12-18 parts of a fixing agent, 2-8 parts of an anti-coagulation agent, 2-10 parts of a buffer agent, 0.5-0.8 part of an ion strength maintaining agent, 2-8 parts of an antimicrobial reagent, 0.05-0.2 part of a mucus dissolving agent and 0.1-0.4 part of a cleanser. The liquid-base cell preservation liquid has the advantages that the cell stability is high, cells are well fixed, the cost is low, the preserved cell forms are relatively complete, and the like. Besides, the invention further provides the preparation method of the liquid-basecell preservation liquid and application of the liquid-base cell preservation liquid in human body cast-off cells.

The present invention relates to a compound medicine for preventing and curing angiocardiopathy and cerebrovascular disease, belonging to the field of chemical medicine. It is characterized by that said compound medicine includes sexual hormones medicine, lipid-reducing medicine, hypotenser, hypoglycemic medicine and anticoagulant medicine. Said compound medicine can be made into various dosage forms. Besides, said compound medicine also can be used for curing the diseases of climacteric syndrome, osteoporosis, endometrial carcinoma, diabetes and metabolic syndrome, etc.

The invention discloses a preparation method of holozoic sea cucumber biological wine, characterized in that the method comprises the steps of: firstly soaking dry sea cucumber in warm water, filtering the sea cucumber, and leaching the aqueous solution to obtain sea cucumber soaking solution; cutting the soaked sea cucumber along the abdomen, clearing the internal organs and the limestone, flushing the sea cucumber through running water, and crushing the sea cucumber to obtain sea cucumber powder; and then, adding the sea cucumber powder in the sea cucumber soaking solution, adding neutral protease, stirring, regulating the pH to 7-8, heating to 45-48 DEG C, hydrolyzing at a constant temperature for 12-18 h, filtering, heating the filtrate to 80-90 DEG C, deactivating enzyme for 10-15 min, cooling, adding sugar substrate, common fermenting for 2-16 weeks, modulating through Chinese medicinal herb leaking solution and filtering to obtain the finished product. The prepared wine contains sea cucumber characteristic ingredients such as sea cucumber polysaccharide sulfate, sea cucumber saponin, sea cucumber amino acid and sea cucumber collagen peptide, and the wine has the functions of anti-tumor, immunity improvement, anti-coagulation, anti- thrombus, anti-radiation, anti-virus, liver protection and blood vessel protection.

The invention relates to a preparation of anti-coagulation dermis scaffold which is used for skin injury repair and has good three-dimensional porous structure. The scaffold preparation uses three natural biologicals of regeneration silk fibroin, chitosan and heparin as raw materials, wherein, heparin has outstanding anti-coagulation property. The dermis scaffold has high porosity and aperture size appropriate for dermal cells to grow; the scaffold has better mechanical property and good hydrophily; the artificial dermis scaffold has heparin slow release function, so that the protrombin time, partial thromboplastin time and thrombin time thereof can be obviously prolonged, thus proving that the dermis scaffold has excellent anti-coagulation property.

The present invention relates to antibiotic dressing for treating injury of mammal, especially human body, and is especially a kind anti-coagulation nano silver antibiotic dressing prepared via anti-coagulation technology. The antibiotic dressing includes a kind of fabric and composite nano silver particles deposited onto the fabric, and the composite nano silver particles in the size of 1-100 nm are attached firmly between the fiber elements and on the fiber. The composite particles have core of metal silver and surface layer of silver oxide, which accounts for 10-80 wt% of the whole composite particles, and the silver content of the dressing is less than 50 microgram each squared millimeter.

Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction with a blood sample of a living being. Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or an ISI, and may be carried out with the patient sample and a coagulation reagent, where the coagulation reagent may be selected from a number of coagulation reagents. One embodiment provides an INRs value which is determined from a prothrombin time (PT or T1) of a patient blood sample and a theoretical end of test time (TEOT), where a theoretical clotting area is used to determine the INRs value according to the expression, INRs=T1*TEOT*MUL, where MUL is a multiplier that takes into account pixel parity and sampling times. The INRs may be used to determine a course of treatment for a patient or other living being without regard to the specific coagulation regent used to generate the coagulation data (e.g., time and optical activity values).

The invention relates to a method for brewing wine by using wormwood, which comprises the following steps: (1) taking 100 parts of glutinous rice by mass, placing in water for soaking for 4-8 hours, scooping up the glutinous rice, cooking, spreading for cooling till 20-28 DEG C, adding 0.5-0.6 part of syeast by mass, evenly stirring and placing into a container; (2) adding 5-10 parts of pure rice wine of 50 degrees by mass after carrying out fermentation of the cooked glutinous rice for 12-20 hours, evenly stirring, squeezing after 100-200 days of sealed fermentation and obtaining juice; (3) taking 0.5-2.5 parts of dry wormwood by mass, adding into 5-10 parts of pure rice wine of 35 degrees by mass for leaching for 3-5 hours and obtaining leaching solution; and (4) mixing the juice with the leaching solution, then heating to 80-90 DEG C, keeping the temperature to 6-8 hours, cooking, removing the wormwood, filtering and obtaining the wine. The wine prepared by the invention has stable wine quality, mellow taste, fragrance and rich nutrition and is rich in amino acids, vitamins and the like, and the wine brewed by the wormwood has the effects of dredging meridians, promoting blood circulation, stopping bleeding, anti-coagulation, anti-bacteria, anti-virus and enhancing immunity.

The invention discloses a blood purification membrane with an anticoagulant property and a preparation method thereof. The blood purification membrane comprises a matrix, a polydopamine layer attachedto the surface of the substrate, argatroban grafted on the polydopamine layer and glutathione. The whole surface modification process is simple in experimental conditions, has strong controllability,and is economical and environmentally-friendly; the high-efficiency anti-coagulation on the local part of a material is realized; the blood coagulation system of a body is not affected; the blood compatibility is significantly improved; and the grafted anticoagulant drug argatroban has no antigenicity and does not cause heparin-induced thrombocytopenia.

The invention relates to a preparation method of an anti-coagulation hemodialysis membrane. The preparation method includes the steps of: a) adding acrylonitrile and ethyl methacrylate into a reaction kettle according to mass ratio of 0.1-5.5:1, stirring the mixture and dropwise adding a polymerization initiator to initiate free radical polymerization to obtain an acrylonitrile-ethyl methacrylate copolymer; b) blending 1-5.5% of the acrylonitrile-ethyl methacrylate copolymer, 12-18% of polysulfone, 1-12% of an additive, and 65-85% of a solvent to prepare a membrane solution, and spinning the membrane solution to manufacture hollow-fiber hemodialysis membrane; and c) dissolving an active monomer containing an alkene double bond and a hydrophilic group in deionized water, and adding a cerium ammonium nitrate grafting initiator to prepare a soaking water solution, and soaking the hollow-fiber hemodialysis membrane in the soaking water solution to initiate a grafting reaction of the active monomer on the surface of the hollow-fiber hemodialysis membrane, and cleaning the hollow-fiber hemodialysis membrane. The surface hydrophilicity of the hemodialysis membrane is significantly improved. The hemodialysis membrane has high biocompatibility and anti-coagulation performance.

Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally before or during bypass surgery on diseased coronary, peripheral, and cerebral arteries, surgery to implant grafts or transplanted organs, or angioplasty, or to stabilize unstable plaques. In an alternative embodiment, the apolipoprotein is not provided directly, but the gene encoding the apolipoprotein is provided. The gene is introduced into the blood vessel in a manner similar to that used for the protein, where the protein is then expressed. The technique can also be used for delivery of genes for treatment or prevention or restenosis or other cardiovascular diseases. In yet another embodiment, stents are coated with apolipoproteins alone, apolipoproteins formulated with lipids, genetically engineered cells expressing the apolipoproteins, naked DNA coding for an apolipoprotein, or other drugs such as anti-proliferatives for local delivery to an injury site. In a preferred embodiment, the system is used with combination therapy, with for local delivery of an agent such as an apolipoprotein in combination with systemic anti-hypertension therapy, anti-inflammatoy therapy, lipid regulation and/or anti-coagulation therapy. These treatments can begin prior to, concurrent with or following local delivery.

The invention relates to a lubricant which is used for high-speed conveyer apron production lines of PET bottles, glass bottles, ring-pull cans and the like and belongs to the filed of chemical lubricant. The proportion of the water-based chain lubricant is that oleic acid triethanolamine 3-8%, triethanolamine 4-9%, LF-131 2-5%, isothiazolin-ketone 1-3%, polymaleic acid 0.5-2%, glucuronidase 4-9%, EDTA-2Na 4-10%, benzotriazole 0.5-2%, sodium sulfonate xylene 0.5-2% and H2O 65-75%, wherein the water-based chain lubricant has high lubricating property and good solubility and is provided with a plurality of excellent performances as anti-hard water, sterilization, low-foam, non-corrosiveness, crack resistance, anti-coagulation and the like, when the lubricant is used in a lubricating system, the bottles inverting ratio can be effectively reduced, the workshop environment can be improved, and the service life of scraping belts cab be prolonged.

A method for preparing micro-molecular hemepeptide from duck blood includes that the duck blood which is a meat duck processing byproduct is used as a raw material, and an anti-coagulation and anti-oxidation technology, a high and low temperature changing alternation technology, a dynamic ultrahigh-pressure technology, a phased enzymatic hydrolysis technology, an enzymatic hydrolysis supernatant decoloration treatment and membrane fractionation technology, spray-drying technology and the like are integrated to develop the micro-molecular hemepeptide with physiological activity within a specific molecular weight range. The average peptide chain length of the micro-molecular hemepeptide prepared by the method ranges from 2.9 amino acid residues to 3.5 amino acid residues, the molecular weight distribution range of the micro-molecular hemepeptide is 1000-3000d, and the content of hemepeptide is higher than or equal to 35%. The method has the advantages that an additional value of the product is increased, duck blood resources are totally, effectively and comprehensively utilized, a preparation process is free of pollutant discharge, and an ecological benefit of zero environmental pollution can be achieved.

The invention discloses a blood cake specimen collecting and treating method and a collection card dry blood cake DNA (deoxyribose nucleic acid) extracting method thereof. The blood cake specimen collecting and treating method includes steps of (1), collecting blood; (2), treating collection card blood cakes; (3), preserving the collection card dry blood cakes; and (4), transferring the collection card dry blood cakes. The blood cake specimens can be preserved at normal temperature, easy to transport, convenient to deliver for examination, and can substitute for anti-coagulation blood as DNA extracting specimen for genetic diagnosis.

The invention provides a cellularization biological liver stent with an anticoagulation property and a preparation method of the cellularization biological liver stent. The preparation method comprises the following steps: (a) pouring a solution containing heparin and/or heparinate into the cellularization biological liver stent, wherein the pouring speed is 80mL/min-150mL/min, and the pouring time is 5-12 hours; and (b) carrying out sterilization. The prepared cellularization biological liver stent is strong in anticoagulation property and good in cytocompatibility and plays a very important support role in the survival, differentiation and proliferation of cells planted on the cellularization biological liver stent, and a convenient and cheap source and the preparation method are provided for the construction of a heterologous tissue-engineered biological anti-coagulation stent with a clinical application value.

The invention relates to a heparin derivative polysaccharide mixture and a preparation method and a medicinal composition thereof. Specifically, the heparin derivative polysaccharide mixture of the invention is a degradation product of heparin or heparin ester or heparin ester salt and is characterized in that the weight-average molecular weight is 3,100 to 4,500 Daltons, the activity of anti-coagulation factor Xa is high, and the activity of anti-coagulation factor IIa is low. The heparin derivative polysaccharide mixture of the invention has excellent antithrombotic performance, low side effect, and has no residues of adverse components such as organic base and dermatan sulfate and the like.

The invention discloses a blood perfusion device having the anti-coagulation function and the controlled-release function and a manufacturing method of the blood perfusion device. The blood perfusion device comprises a perfusion device body provided with an adsorption chamber. The adsorption chamber contains an adsorbent and anti-coagulation and controlled-release gel having the thermosensitive characteristic. The anti-coagulation and controlled-release gel contains anti-coagulation matter. The anti-coagulation and controlled-release gel can be formed by dissolving the anti-coagulation matter, a compound with the two ends containing double bonds and a N-alkyl acrylamide type monomer having the thermosensitive characteristic in water through polymerization. By the adoption of the blood perfusion device having the anti-coagulation function and the controlled-release function, the anti-coagulation function is integrated with the blood purification function, the convenience of clinical blood perfusion is improved, and the risk of introducing pyrogen additionally is avoided; the thermosensitive characteristic and the mechanical property of the anti-coagulation and controlled-release gel can be adjusted by changing reactant components, the crosslinking density, the ion strength and the water content; when coagulation happens, coagulated blood clots can squeeze the anti-coagulation and controlled-release gel, so that release of the anti-coagulation matter can be instantly accelerated by the anti-coagulation and controlled-release gel, and the effect of effectively preventing the coagulation range from expanding is achieved.